Benutzerspezifische Werkzeuge
Startseite Kompetenznetz Hepatitis

Das Kompetenznetz Hepatitis

Das „Kompetenznetz Hepatitis“, kurz Hep-Net, ist ein Zusammenschluss von namhaften Experten auf dem Gebiet der Hepatitis in Deutschland.

Das Hep-Net wurde 2002 vom Bundesministerium für Bildung und Forschung gegründet, um die bundesweite Erforschung von virusbedingten Leberentzündungen und die Versorgung von Patienten mit einer chronischen Virushepatitis zu verbessern. Die virusbedingte Leberentzündung ist eine der weltweit häufigsten Infektionskrankheiten, in Deutschland sind etwa eine Million Menschen davon betroffen. Seit 2007 ist die Deutsche Leberstiftung Trägerin des „Kompetenznetz Hepatitis“, um die erfolgreiche Arbeit des Forschungsverbundes nach Auslaufen der öffentlichen Förderung 2010 fortzuführen.

In verschiedenen Projekten wird das Hauptziel der Deutschen Leberstiftung und des „Kompetenznetz Hepatitis“ verwirklicht: Die Verbesserung der Patientenversorgung durch Forschungsvernetzung.

Publikationen
Im Rahmen des „Kompetenznetz Hepatitis“ sind zahlreiche Publikationen entstanden. Die vollständige Liste finden Sie nachfolgend.

 

Autor/en Titel Zeitschrift/Buch
Amini-Bavil-Olyaee S, Sheldon J, Lutz T, Trautwein C, Tacke F. Molecular analysis of an HBsAg-negative Hepatitis B Virus mutant selected in a tenofovir-treated HIV-HBV co-infected patient. AIDS: 23(2):268-72, 2009
Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in HBeAg-positve and HBeAg-negative Hepatitis B Virus strains. Hepatology:2009
Kovalenko, E., Tacke, F., Gressner, O. A., Zimmermann, H., Lahme, B., Janetzko, A., Wiederholt, T., Berg, T., Müller, T., Trautwein, C., Gressner, A. M., Weiskirchen, R. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as non-invasive biomarkers for the assessment of liver fibrosis. J. Viral Hepatitis:2009
Mohren, S., Weiskirchen, R. Non-synonymous gene polymorphisms in the secretory signal peptide of human TGF-1 affect cellular synthesis but not secretion of TGF-1. Biochem. Biophys. Res. Commun.: 379, 1015-1020, 2009
Wasmuth, H. E., Lammert, F., Moreno Zaldivar, M., Weiskirchen, R., Scholten, D., Hellerbrand, C., Berres, M. L., Tacke, F., Hillebrandt, S., Wiederholt, T., Schmitz, P., Keppeler, H., Berg, T., Dahl, E., Gassler, N., Friedman, S.L., Trautwein, C. CXCL9 and its receptor CXCR3 are a chemokine-based antifibrotic pathway in the liver. Gastroenterology: 2009
Wedemeyer I, Bechmann L, Odenthal M, Jochum C, Marquitan G, Drebber U, Guido Gerken G, Gieseler R, Dienes HP, Canbay A. Adiponectin Inhibits Steatotic CD95/Fas Upregulation by Hepatocytes: Therapeutic Implications for Hepatitis C. Journal of Hepatology: Jan;50(1):140-9, 2009
Bechmann L, Zahn D, Gieseler RK, Fingas CD, Marquitan G, Jochum C, Gerken G, Friedman S, Canbay A. Resveratrol Amplifies Profibrogenic Effects of Free Fatty Acids on Human Hepatic Stellate Cells. Hepatology Research: 2009
Canbay A, Jochum C, Bechmann L, Festag S, Yüksel Z, Saner F, Gerken G. Retrospective Study of Acute Liver Failure in Residents of a Metropolitan Area in Germany: Correlation of Cholestatic Enzymes and Body Mass Index with Clinical Outcome. Z Gastroenterol: 2009
Dintsios, Charalabos-Markos; Haverkamp, Alexander; Wiegand, Johannes; Gerlach, Tilman; Wedemeyer, Heiner; Pape, Gerd; Manns, Michael Peter; Krauth, Christian. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. European Journal of Gastroenterology & Hepatology: 22 June doi: 10.1097/MEG.0b013e32832c7b2e, 2009
Niederau C, Bemba G, Kautz A. Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project. Z Gastroenterol: 46(1):22-33, 2008
Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoël M, Dreux M, Baumert TF. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology: 135(5):1719-1728, 2008
Ross RS, Viazov S, Clauberg R, Wolters B, Fengler I, Eveld K, Scheid-hauer R, Hüsing J, Philipp Th, Kribben A, Roggendorf M. Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. J Viral Hepat: (doi:10.111/j.1365-2893.2008.01068.x), 2008
Ross RS, Verbeeck J, Viazov S, Lemey P, Van Ranst M, Roggendorf M. Evidence for a complex mosaic genome pattern in a full-length hepatitis C virus sequence. Evol Bioinformatics: 4: 249 – 254, 2008
Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM,Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. (Kooperationsprojekt) Hepatology: 48(6):1769-78, 2008
Salloum S, Oniangue-Ndza C, Neumann-Haefelin C, Hudson L, Giugliano S, aus dem Siepen M, Nattermann J, Spengler U, Lauer GM, Wiese M, Klenerman P, Bright H, Scherbaum N, Thimme R, Roggendorf M, Viazov S, Timm J. Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol.: 82(23):11803-12, 2008
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C;v Hep-Net B/C Co-infection Study Group. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol: 49(5):688-94, 2008
Leifeld L, Merk P, Schmitz V, Nattermann J, Kalff JC, Hirner A, Sauerbruch T, Spengler U. Course and therapy of acute liver failure. Eur J Med Res.: 25;13(2):87-91, 2008
Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS.: 11;22(2):203-10, 2008
Scholten D, Trautwein C, Weiskirchen R, Zaldivar MM, Hellerbrand C, Hillebrandt S, Wiederholt T, Schmitz P, Goos C, Keppeler H, Berg T, Friedman SL, Dahl E, Donner A, Lorenzen J, Lammert F, Wasmuth HE CXCL9 and its receptor CXCR3 are a chemokine-based
antifibrotic pathway in the liver J Clin Invest, 2008
Petersen J., Dandri D., Mier W., Lütgehetmann M., Volz T., von Weizsäcker F., Haberkorn U., Fischer L., Pollok J.-M., Erbes B., Seitz S., Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein Nature Biotechnology: 26 (3):335-341, 2008
Hüppe D, Zehnter E, Mauss S, Böker K, Lutz T, Racky S, Schmidt W, Ullrich R, Sbrijer L, Heyne R, Schober A, John C, Hey KH, Bokemeyer B, Kallinowski B, Möller B, Pape S, Gutmann M, Alshuth U, Niederau C. Epidemiologie der chronischen Hepatitis C in Deutschland - Eine Analyse von 10.326 Hepatitis C Infizierten aus Schwerpunktpraxen und -ambulanzen. Z Gastroenterol: 46 (1); p. 34-44, 2008
Ciesek S, Liermann H, Cornberg M, Tillmann HL, Kezmic N, Manns MP, Wedemeyer H. Impaired TRAIL-dependent cytotoxic activity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepatitis: 15 (3); p. 200-11, 2008
H.P. Dienes, U. Drebber Aktuelle Probleme der Hepatitis. Der Pathologe: 1-4, 2008
H. Varnholt, U. Drebber, F. Schulze, I. Wedemeyer et al. MicroRNA Gene Expression Profile of Hepatitis C Virus-associated Hepatocellular Carcinoma. 1223, 2008
S. Schulte, A. Oidtmann et al. International Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis. Liver 1478-3223, 2008
K. Schwamborn, R. Krieg, O. Gressner et al. Proteomic profiling of serum by MALDI-TOF mass spectrometry is a promising diagnostic technique to analyze the severity and progression of fibrinogesis associated with chronic hepatitis infection. Journal of Hepatology: 2008
J. Hirschfeld, J. Maurer, D. Jung et al. Targeting myofibroblasts in model systems of fibrosis by an artificial α-smooth muscle-actin promoter hybrid. 2008
M. Quasdorff, M. Hösel, M. Odenthal et al. A concerted action of HNF4α and HNF1α links hepatitis B virus replication to hepatocyte differentiation. Cellular Microbiology: 10 (7), 1478-1490, 2008
I. Wedemeyer, L. Bechmann, M. Odenthal, C. Jochum et al Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: Therapeutic implications for hepatitis C. Journal of Hepatology: 2008
Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, Thomas Berg, Tobias Goeser, Ulrich Spengler, Holger Hinrichsen, Hans Weidenbach, Guido Gerken, Michael Manns, Peter Buggisch, Eva Herrmann and Stefan Zeuzem. Placebo-Controlled Trial of 400 mg Amantadine Combined with Peginterferon Alfa-2a and Ribavirin for 48 Weeks in Chronic Hepatitis C Virus-1 Infection. Hepatology: 2008
Marschall T, Prüfer-Krämer L, Krämer A. Versorgung von Patienten mit chronischer Hepatitis B. MMW Fortschr Med: 150 (Suppl. 3):105-11., 2008
Wörmann T, Prüfer-Krämer L, Krämer A. Serologische und soziodemographische Unterschiede bei HBV-Patienten mit und ohne Migrationshintergrund - ein Beitrag zur Versorgungsforschung bei Patienten mit chronischer Hepatitis B. Deutsches Ärzteblatt: 2008
Marschall T, Prüfer-Krämer L, Krämer A. Versorgung von Patienten mit chronischer Hepatitis B in hepatologischen Ambulanzen in Deutschland: hoher Anteil von Migranten der ersten Generation! Tagungsband der 3. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), Bielefeld, 24. – 27. September 2008. Landesinstitut für Gesundheit und Arbeit Nordrhein-Westfalen (Hrsg.), Düsseldorf: Seite 196., 2008
Marschall T, Prüfer-Krämer L, Krämer A. Medical care of patients with chronic hepatitis B infections in Germany: high proportion of first generation migrants! European Journal of Public Health: 18(Suppl.1):220 (16th EUPHA Conference, Lissabon, 6.-8. November 2008)
Grünhage F, Rezori B, Neef M, Lammert F, Sauerbruch T, Spengler U, Reichel C. Elevated soluble tumor necrosis factor receptor 75 concentrations identify patients with liver cirrhosis at risk of death. Clin Gastroenterol Hepatol.: 6(11):1255-62, 2008
Weber S, Gressner OA, Hall R, Grünhage F, Lammert F. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans. Clin Liver Dis.: 12(4):747-57 vii., 2008
Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, Schmitz P, Dahl E, Wiederholt T, Hellerbrand C, Berg T, Weiskirchen R, Trautwein C, Lammert F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol: 48(2):208-15, 2008
Joerg Petersen, Maura Dandri, Walter Mier, Marc Lütgehetmann, Tassilo Volz, Fritz von Weizsäcker, Uwe Haberkorn, Lutz Fischer, Joerg-Matthias Pollok, Berit Erbes, Stefan Seitz uns Stephan Urban. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology: Feb. 2008
Salguero Palacios R, Roderfeld M, Hemmann S, Rath T, Atanasova S, Tschuschner A, Gressner OA, Weiskirchen R, Graf J, Roeb E. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest.: Nov;88(11):1192-203. Epub Sep 15 ,2008
Neumann-Haefelin C, Timm J, Spangenberg HC, Wischniowski N, Nazarova N, Kersting N, Roggendorf M, Allen TM, Blum HE, Thimme R Virological and Immunological Determinants of Intrahepatic Virus-Specific CD8+ T-Cell Failure in Chronic Hepatitis C Virus Infection. Hepatology: 47: 1824-1836, 2008
Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J Analysis of the evolutionary forces in an immunodominant CD8 epitope in the hepatitis C virus at a population level. J Virol.: 82: 3438-3451, 2008
Salloum S, Oniangue-Ndza C, Neumann-Haefelin C, Hudson L, Giugliano S, aus dem Siepen M, Nattermann J, Spengler U, Lauer G, Wiese M, Klenerman P, Bright H, Scherbaum N, Thimme R, Roggendorf M, Viazov S, Timm J Escape from HLA-B*08 restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol: 82:11803-11812, 2008
Wasmuth, H. E., Moreno Zaldivar, M., Berres, M. L., Werth, A., Scholten, D., Hillebrandt, S., Tacke, F., Schmitz, P., Dahl, E., Wiederholt, T., Hellerbrand, C., Berg, T., Weiskirchen, R., Trautwein, C., Lammert, F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J. Hepatol.: 48, 208-215., 2008
Weiskirchen, R. Borkham-Kamphorst, E., Meurer, S. K., Drews, F., Mohren, S., Herrmann, J., Gressner, O. A., Scherner, O., Vreden, W. N., Kovalenko, E., Bomble, M., Gressner, A. M. A complex network of intra- and intercellular mediators regulate cellular activation and transdifferentiation of hepatic stellate cells. J. Bosch, A. K. Burroughs, F. Lammert, D. Lebrec, T. Sauerbruch (eds). Springer Verlag, Heidelberg, Germany: S. 45-69. ISBN: 978-1-4020-8655-7, 2008
Salguero Palacios, R., Roderfeld, M., Hemmann, S., Rath, T., Atanasova, S., Tschuschner, A., Gressner, O. A., Weiskirchen, R., Graf, J., Roeb, E. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab. Invest.: 88, 1192-1203, 2008
Tag, C. G., Gressner, A. M., Weiskirchen, R. Rapid FSAP genotyping of the E393Q (Marburg II) and G534E (Marburg I) polymorphisms on the LightCycler in a multiplex PCR using two fluorescently labeled probe sets. The Open Clin. Chem. J.: 1, 42-46., 2008
Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, Schmitz P, Dahl E, Wiederholt T, Hellerbrand C, Berg T, Weiskirchen R, Trautwein C, Lammert F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol: 48(2):208-215, 2008
Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, Trautwein C, Deppe H, Schulz TF, Heim H, Tacke F. Symptomatic Hepatitis B Virus (HBV) Reactivation despite Reduced Viral Fitness Is Associated with HBV Test and Immune Escape Mutations in an HIV-Coinfected Patient. J Infect Dis: 198(11):1620-4, 2008
Tacke F, Trautwein C. Hepatitis B goes globe – telbivudine as a new treatment option. Hepatology: 47(5):1786-1787, 2008
Halverscheid L, Mannes NK, Weth R, Kleinschmidt M, Schultz U, Reifenberg K, Schirmbeck R, Nassal M, Blum HE, Reimann J, Geissler M. Transgenic mice replicating hepatitis B virus but lacking expression of the major HBsAg. J Med Virol: Apr;80(4):583-90, 2008
Reil H, Bartlime A, Drerup J, Grewing T, Korn K. Clinical validation of a new triplex real-time polymerase chain reaction assay for the detection and discrimination of Herpes simplex virus types1 and 2. J Mol Diagn: Jul;10(4):361-7, 2008
Bennour E., Ferrand C., Rémy-Martin J.P., Certoux J.M., Gorke S., Qasim W., Gaspart H.B., Baumert T., Duperrier A., Deschamps M., Fehse B., Tigerghien P., Robinet E. Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum. Gene. Ther.: 19, 699-709., 2008
Haberstroh A., Schnober E.K., Carolla P., Zeisel M.B., Barth H., Gissler B., Blum H.E., Cosset F.L., Koutsoudakis G., Bartenschlager R., Depla E., Owsianka A., Patel A.H., Schuster C., Stoll-Keller F., Doffoel M., Dreux M., Baumert T.F. Neutralizing host responses in hepatitis C virus infection target viral entry at post-binding steps and membrane fusion. Gastroenterology: 135, 1719-1728, 2008
Lan L., Gorke S., Rau S.J., Zeisel M.B., Hildt E., Himmelsbach K., Carvajal-Yepes M., Huber R., Wakita T., Schmitt-Graeff A., Royer C., Blum H.E., Fischer R., Baumert T.F. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J. Immunol.: 181, 4926-35, 2008
Dimitrova M., Affolter C., Meyer F., Nguyen I., Richard D.G., Schuster C., Bartenschlager R., Voegel J.C., Ogier J., Baumert T.F. Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc. Natl. Acad. Sci.: 105, 16320-25, 2008
Zeisel M.B., Cosset F.L., Baumert T.F. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology: 48, 299-307, 2008
Schulte S, Oidtmann A, Kociok N, Demir M, Odenthal M, Drebber U, Dienes HP, Nierhoff D, Goeser T, Toex U, Steffen HM Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis. Liver Int, 2008
Quasdorff M, Hosel M, Odenthal M, Zedler U, Bohne F, Gripon P, Dienes HP, Drebber U, Stippel D, Goeser T, Protzer U A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol: 10:1478-90, 2008
Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology: 47:1223-32, 2008
C. Oniangue-Ndza, M. aus dem Siepen, V. Lohmann, M. Wiese, S. Viazov, M. Roggendorf In vitro replicative properties of replicons constructed using sequence variants of the hepatitis C virus strain AD78 that caused a single-source outbreak of hepatitis C. Virus Research, 2008
Lupberger J., Zeisel M.B., Haberstroh A., Schnober E.K., Krieger S., Soulier E., Thumann C., Royer C., Fafi-Kremer S., Schuster C., Stoll-Keller F., Blum H.E., Baumert T.F. Virus-host interactions during hepatitis C virus entry – Implications for pathogenesis and novel treatment approaches. In: “Virologica Sinica” (X. Chen, M. Lu and D. Yang eds.): 22, 124-131, 2008
Christian Mölleken, Barbara Sitek, Corinna Henkel, Gereon Poschmann, Bence Sipos, Sebastian Wiese, Bettina Warscheid, Christoph Broelsch, Markus Reiser, Scott L. Friedman, Ida Tornoe, Anders Schlosser, Günter Klöppel, Wolff Schmiegel, Helmut E. Meyer, Uffe Holmskov and Kai Stühler Detection of Novel Biomarkers of Liver Cirrhosis by Proteomic Analysis Hepatology: 2008
Bechmann L, Marquitan G, Jochum C, Saner F, Gerken G, Canbay A. Apoptosis vs. Necrosis Rate as a Predictor in Acute Liver Failure following Acetaminophen Intoxication compared to Acute-on-Chronic Liver Failure. Liver Inter.: 28:713-6, 2008
Vauth C, Haverkamp A, Mittendorf T, Siebert U, Schulenburg JM, Krauth C *Das Kompetenznetz Hepatitis – Methodische Ansätze und erste Ergebnisse der gesundheitsökonomischen Begleitforschung* Gesundheitsökonomie & Qualitätsmanagement: Vol. 12, Nr. 4, S. 203-206, 2007
Wedemeyer H, Cornberg M, Protzer U, Berg T, Dollinger MM [German guidelines on diagnosis and therapy of hepatitis B] Dtsch Med Wochenschr.: 132: 1775-82, 2007;
Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP: [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. Z Gastroenterol.: 45: 525-74, 2007
Schott E, Witt H, Neumann K, Taube S, Oh D-Y, Schreier E, Vierich S, Puhl G, Bergk A, Halangk J,Weich V, Wiedenmann B, Berg T A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J. Hepatology: 47, 208-211, 2007
Mueller T, Gessner R, Sarrazin C, Koettgen E, Halangk J, Schott E, Bergk A, Weich V, Schlosser B, Wiedenmann B, Berg T:. Apolipoprotein E4 (APOE4) allele protects from chronic Hepatitis C virus (HCV) infection Hepatology: 46 S1: 635A, 2007
Mhamdi M, Funk A, Hohenberg H, Will H, Sirma H. Assembly and budding of a hepatitis B virus is mediated by a novel type of intracellular vesicles. Hepatology: 46(1),95-106, 2007
Schott E, Witt H, Weich V, Halangk J, Bergk A, Wiedenmann B, Berg T: Associatiion of TLR7 polymorphisms with response to interferon-alpha-based therapy in patients with chronic HCV infection. J Hepatol: 46: S176, 2007
Schott E, Witt H, Pascu M, van Boemmel F, Weich V, Bergk A, Halangk J, Müller T, Puhl G, Wiedenmann B, Berg T. Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol: 19: 947-951, 2007
Funk A, Mhamdi M, Will H, Sirma H. Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism. World J Gastroenterol.: 7,13(1),91-103 Review., 2007
Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Pape G, Spengler U, Buggisch P, Balk H, Zankel M, Sarrazin C, Zeuzem S: Bedeutung einer minimalen Restvirämie für die Relapse-Prädiktion bei individualisierter oder Standard-Therapiedauer bei Hepatitis C Virus (HCV) Typ 1-Infektion (Indiv-1 Studiengruppe). Z Gastroenterol: 45: 735, 2007
Weich V, Schlosser B, Halangk J, Bergk A, van Bömmel F, Berg T: Bezafibrate treatment for chronic Hepatitis C after failure of previous combination therapy with interferon and ribavirin. Hepatology: 46 S1: 368A, 2007
Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H, Baumert TF, Dubuisson J, Wakita T. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol.: 81(10):5036-45, 2007
Meyer MF, Lehmann M, Wiegand J, Cornberg M, Klade C, Manns MP, Wedemeyer H. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virology J : 4, 58, 2007
Deterding K., Pothakamuri S.V., Schlaphoff V., Hadem J., Metzler F., Bahr M.J., Manns M.P., Cornberg M., Wedemeyer H.: Clearance of Chronic HCV Infection During Acute Delta Hepatitis Infection 2007
Welker MW, Hofmann WP, Welsch C, von Wagner M, Herrmann E, Lengauer T, Zeuzem S, Sarrazin C. Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients. J Viral Hepat: 14,338-49, 2007
Stickel E, Oesterreicher C, Schneider V, Halangk J, Berg T, Patsenker E, Homann N, Hellerband C, Kolb A, Friess H, Schuppan D, Seitz HK: Critical evaluation of candidate gene polymorphisms in the development of alcoholic liver cirrhosis. J Hepatol: 46: S286, 2007
Gerlich, W.H., Glebe, D., Schüttler, C.G. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus J Viral Hepatitis: 14, 1-6, 2007
Berg T, Weich V, von Wagner M, Hinrichsen H, Schmidt W, Kallinowski B, Klinker H, Spengler U, Alshuth U, Zeuzem S: Definition eines virologischen „Cut-offs“ zur Optimierung der Therapiedauer bei Hepatitis C Virus (HCV) Typ 1-Infektion. Z Gastroenterol: 45: 855, 2007
Gerlich, W. H. Diagnose der Hepatitis-B Virusinfektionen In: H. L. Tillmann (Hrsg.) Moderne Behandlungskonzepte bei Hepatitis-B. Unimed Verlag: 2007
Caspari, G.C., Gerlich, W.H. Die serologischen Marker der Hepatitis-B-Virusinfektion – Indikationsgerechte Auswahl und standardisierte Interpretation. Clin. Lab: 53: 91-400, 2007
Derkow K, Loddenkemper C, Mintern J, Kruse N, Klugewitz K, Berg T, Wiedenmann B, Ploegh HL, Schott E: Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology: 46: 1155-1165, 2007
Sirma, H., Funk, A., Gerlich, W.H., Schildgen, O. Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection? Antimicrob Chemother, 2007
Kronenberger B, Zeuzem S, Sarrazin C, Mihm U, von Wagner M, Hofmann WP, Piiper A, Herrmann E. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir. Ther.: 12(5),779-87, 2007
Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S: Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol.: 19: 639-46, 2007
Halangk J, Witt H, Neumann K, Sarrazin C, Hinrichsen H, Fitz C, Puhl G, Wiedenmann B, Neuhaus P, Berg T. Z Einfluss von Angiotensinogen Polymorphismen auf die Fibroseprogression bei chronischer Hepatitis C und anderen Lebererkrankungen. Gastroenterol: 1: 94, 2007
Weich V, Schlosser B, Halangk J, Bergk A, van Bömmel F, Berg T. Z Einsatz von Bezafibrat bei Patienten mit chronischer Hepatitis C, die auf eine vorangegangene Kombinationstherapie mit Interferon und Ribavirin nicht angesprochen haben. Gastroenterol: 1: 138, 2007
Niederau C. Epidemiologie der Hepatitis B in Deutschland. Med Klinik: 102,351-7, 2007
Wiegand J, Cornberg M, Aslan N, Sarrazin C, Kubitschke A, Buggisch P, Ciner A, Jaeckel E, Manns MP, Wedemeyer H. Fate and function of peripheral HCV-specific T-cells during peginterferon alpha-2b therapy of acute hepatitis C. Antiviral Therapy: 12, 303-316, 2007
Niederau C. Fettleber: Die stille Gefahr. Seniorenratgeber: 38-41, 2007
Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation: 83: 351-353, 2007
Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns MP, Wedemeyer H. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. Clin Virol: 39, 308-11, 2007
Schlaphoff V, Klade CS, Jilma B, Jelovcan SB, Cornberg M, Tauber E, Manns MP, Wedemeyer H and the IC41 study group. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine: 25, 6793-6806, 2007
Schott E, Witt H, Hinrichsen H, Neumann K, Weich V, Bergk A, Halangk J, Mueller T, Tinjala S, Puhl G, Neuhaus P, Wiedenmann B, Berg T. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infectioin. Hepatol: 46: 372-380, 2007
Martens S, Weich V, Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Spengler U, Klinker H, Zeuzem S, Herrmann E: Genotype-specific assessment of predictive factors for sustained virologic response after standard treatment in patients chronically infected with HCV. J Hepatol: 46: S226, 2007
Gressner O, Meier U, Hillebrandt S, Wasmuth H, Köhl J, Sauerbruch T, Gressner AM, Lammert F. Gc-globulin concentrations and C5 haplotype-tagging polymorphisms contribute to variations in serum activity of complement factor C5. Clin Biochem: 40: 771-775, 2007
Niederau C. Hämochromatose und Eisenüberladung. Der Hausarzt: 29,24-29, 2007
Gerlich, W.H. and 15 coauthors HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity J. Med. Virol.: 79, S1: S32-S36, 2007
Weich V, van Bömmel F und Berg T. HBsAg positiv und normale Transaminasen: ein Risikopatient? 2 Fallbeispiele. Der Hausarzt: 11: 38-41, 2007
Baumert TF, Rosler C, Malim MH, von Weizsacker F. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology.: 46(3):682-9, 2007
Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M, Ziemer M, Gutsche J, Weich V, Halangk J, Berg T: Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology.: 46: 991-998, 2007
Wedemeyer H, Heidrich B, Manns MP Hepatitis D Virus Infection – not a vanishing disease in Europe! Hepatology : 45, 1331-1332. (research letter), 2007
Gerlich, W.H., Caspari, G.C. Hepatitis-B-Virus In: Neumeister et al. (Hrsg)., Burkhardt, Mikrobiologische Diagnostik: 2. Aufl., 2007
Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B, Berg T: Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-alpha. Am J Gastroenterol. Epub: 2. Aufl., 2007
Ulsenheimer A, Paranhos-Baccalà G, Diepolder H, Heeg M, Raziorrouh B, Zachoval R, Pape G, Berg T, Jung MC, Grüner N: Hohe Variabilität des NS3 1406 CD 8 Epitopes mit Entwicklung von Escape Mutationen in der Frühphase der akuten Hepatitis C Virus Infektion. Z. Gastroenterol: 45: 847, 2007
Sanchez-Tapias JM, Ferenci P, Diago M, Romero-Gomez M, Zeuzem S, Berg T: How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peginterferon α-2a (40 kD) plus RBV? J Hepatol: 46: S242; 2007
Hofmann WP, Welsch C, Takahashi Y, Miyajima H, Mihm U, Krick C, Zeuzem S, Sarrazin C. Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia. Scand.J.Gastroenterol: 42(9),1088-94, 2007
Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A.: 104(20):8427-32, 2007
Berg T, Weich V, Teuber B, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Sarrazin C, Zeuzem S: Importance of a minimal residual viremia for the relapse prediction in HCV Typ 1 patients receiving standard or individualized treatment duration. Hepatology: 46 S1: 317A, 2007
Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarrazin C, Greten T, Wiegand J, Manns MP, Wedemeyer H. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viremia. Eur J Clin Invest : 37,54-64, 2007
Caspari, G.C., Gerlich, W.H. Infektionen durch Blut- und Blutprodukte In: Marre et al. (Hrsg.) Klinische Infektiologie: 2007
Bahra M, Jacob D, Neumann UP, Spies F, Langrehr JM, Berg T, Neuhaus R, Neuhaus P: Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C Transplantation: 84: 144-8, 2007
Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U Kompetenznetz HIV/AIDS. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients Hepatology.: 46: 1016-1025, 2007
Rifai K,
Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL. Longer survival of liver transplant recipients with hepatitis virus coinfections. Clin Transplantation: 21, 258-64, 2007
Van Bömmel F, Brodzinski A, Mihm U, Jung MC, Sarrazin C, Bergk A, Schlosser B, Weich V, Schott E, Wiedenmann B, Berg T Multifactorial analysis of host and virus related risk factors for the development of viral resistance during long-term lamivudine treatment of HBV-infection over up to nine years. J Hepatol: 46: S198, 2007
Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, Schonberger B, Zeuzem S, Sarrazin C. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology: 132,921-30., 2007
Niederau C. Neue deutsche und amerikanische Leitlininien zur Therapie der Hepatitis B: Unterschiede und Gemeinsamkeiten. Med Klinik: 102, 763-767, 2007
Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, Baumert TF. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol.: 13(36):4824-30, 2007
Schmöcker C, Weylandt KH, Kahlke L, Wang J, Lobeck H, Tiegs G, Berg T, Kang JX. Omega-3 fatty acids alleviate D-GalN/LPS induced acute hepatitis by supression of cytokines. Hepatology.: 45: 864-9, 2007
Zeuzem S, Fried MW, Torriani F, Zehnter E, Berg T, Lin A, Hadziyannis SJ Optimal treatment HCV-RNA level for prediction of SVR with peginterferon α-2a (40 kD) plus ribavirin in genotype 1 patients: generalised additive logistic regression model (GAM) analysis. J Hepatol: 46: S249, 2007
Bahra M, Neumann UP, Jacob D, Berg T, Neuhaus R, Langrehr JM, Neuhaus P Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transpl Int: 20: 771-8, 2007
Gärtner, B.C., Jung, W., Welsch, C, Fischinger, J.S., Zeuzem, S., Mueller-Lantzsch, N., Wend, U.C., Gerlich W.H. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation J. Clin. Virol.: 38: 146-148, 2007
Bergk A, Neumann UP, van Bömmel F, Wiedenmann B, Berg T, Neuhaus R: Prediction of treatment response to 72 weeks of pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C after liver transplantation. J Hepatol: 46: S218, 2007
Meyer MF, Wedemeyer H*, Monazahian M, Dreesman J, Manns MP, Lehmann M. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiology and Infection, 135,274-280., 2007
Borkham-Kamphorst, E., van Roeyen, C. R., Ostendorf, T., Floege, J., Gressner, A. M., Weiskirchen, R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J. Hepatol.: 46, 1064-1074, 2007
Müller T, Geßner R, Sarrazin C, Halangk J, Wiedenmann B, Berg T: Protektiver Effekt des Apolipoprotein E4 Allels bei Hepatitis C Virus (HCV) Infektion. Z Gastroenterol: 45: 851, 2007
von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken GG, Manns MP, Buggisch P, Zeuzem S: Randomized, double-blind, placebo-controlled trial of peginterferon alfa-2a (40 KD) and ribavirin with and without 400 mg amantadine-sulphate for 48 weeks in treatment naive HCV genotype 1-infected patients. Hepatology: 46 S1: 343A, 2007
Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A.: 104(14):6025-30, 2007
Awerkiew, S., Däumer, M., Reiser, M., Wend, U.C., Pfister, H., Kaiser, R., Willems, W. R., Gerlich, W.H. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J. Clin. Virol: 38: 83-86, 2007
Hofmann WP, Fernandez B, Herrmann E, Welsch C, Mihm U, Kronenberger B, Feldmann G, Spengler U, Zeuzem S, Sarrazin C. Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative disease. J.Viral.Hepat.: 7,484-91, 2007
Mueller T, Mas Marques A, Sarrazin C, Wiese M, Halangk J, Witt H, Wasmuth H, Ahlenstiel G, Spengler U, Lammert F, Schott E, Weich V, Schreier E, Wiedenmann B, Berg T Sow-density lipoprotein receptor (LDLR) Polymorphisms are associated with spontaneous and treatment-induced recovery from Hepatitis C-virus (HCV) infection Hepatology: 46 S1: 629A, 2007
Niederau C, Bemba G, Kautz A. Sozio-ökonomische Charakteristika, Lebensqualität und Wissensstand bei Patienten mit Hepatitis B-Virusinfektion in Deutschland. Z Gastroenterol: 45,355-68, 2007
Potthoff A, Deterding K, Trautwein C, Flemming P, Strassburg CP, Manns MP, Wedemeyer H, Bahr MJ. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol: 45, 15-19, 2007
Schaefer, S., Gerlich, W.H. Structure, replication and laboratory diagnosis of HBV and HDV. In: Benhamou JP, Rizzetto R, Reichen R et al., eds. The Textbook of Hepatology: From Basic Science to Clinical Practice, 3rd ed., Blackwell Publishing, Oxford, 2007
v. Boemmel F, Trojan J, Feucht HH, Moeller B, Hueppe D, Wiedenmann B, Berg T Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir. Hepatology: 46 S1: 664A, 2007
Gerlich W.H. The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg Clin. Infect.: Dis. 44: 1170-2, 2007
Nattermann J, Bueren K, Nischalke HD, Ahlenstiel G, Berg T, Biermer M, Sauerbruch T, Vogel M, Rockstroh JK, Spengler U: The GNB3 C825 T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. J Hepatol: 46: S235, 2007
Ahlenstiel G, Nischalke HD, Bueren K, Berg T, Vogel M, Biermer M, Grünhage F, Sauerbruch T, Rockstroh J, Spengler U, Nattermann J. The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. J Hepatol: 47: 348-55, 2007
Goyal A, Hofmann WP, Hermann E, Traver S, Hissar SS, Arora N, Blum HE, Zeuzem S, Sarrazin C, Sarin SK. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol (Berl): 196,11-21 (Geteilte Erstautorschaft), 2007
Caspari, G.C., Gerlich, W.H. The serologic markers of hepatitis B virus infection - proper selection and standardized interpretation. Clin. Lab: 53: 335-343, 2007
Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Sarrazin C, Zeuzem S: Time to HCV RNA negativation in Hepatitis C virus (HCV) type 1-infection during peg-interferon-slpha-2b plus ribavirin therapy: differences in relation to the assay sensitivity (INDIV-1 Study Group). Hepatology: 46 S1: 360A, 2007
Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Gruner N, Rauch A, Gerlach JT, Jung MC, Zachoval R, Pape GR, Schraut W, Santantonio T, Nitschko H, Obermeier M, Phillips R, Scriba TJ, Semmo N, Day C, Weber JN, Fidler S, Thimme R, Haberstroh A, Baumert TF, Klenerman P, Diepolder HM Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS ONE.: 2(7):649, 2007
Trebst C, Wedemeyer H, Manns MP, Tillmann H, Windhagen A. Treatment of HCV associated inflammatory polyneuropathy with pegylated IFN-alpha and Ribavirin. Eur J Gastroenterol Hepatol (case report): 19, 91-92, 2007
Meyer MF, Handke GU, Wiegand J, Manns MP, Wedemeyer H, Lehmann M. Verbesserung des objektiven und subjektiven Gesundheitszustandes von Drogenabhängigen nach Inhaftierung: Eine prospektive Untersuchung in der Jugendanstalt Hameln. Suchtmedizin: 9, 113-121, 2007
Gerlich, W.H., Schüttler C.G. Vermeintlich überstandene Hepatitis-B-Virusinfektion – mögliche Probleme. In: H. Selmair, M.P. Manns Virushepatitis als Berufskrankheit: S.128-137, 2007
Glebe, D. and Urban, S. Viral and cellular determinants involved in hepadnaviral entry. (Review) World J. Gastroenterol.: 13(1), 22‐38 , 2007
Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin.Microbiol.Rev.: 20:23-38, 2007
Marcellin P, Hadziyannis SJ, Berg T, Sanchez-Tapias JM, Bronowicki JP, Sakai T, Lin A, Tietz A, Ferenci P: Virological response at 4 and 12 weeks predict hiegh rates of sustained virological response in genotype 1 patients treated with peginterferon α-2a (40 kD) plus ribavirin. J Hepatol: 46: S231, 2007
Van Bömmel F, Trojan J, Möller B, Feucht HH, Hüppe D, Berger A, Wiedenmann B, Berg T: Wirksamkeit von Tenofovir bei HBV-Infektionen mit genotypischer Adefovir-Resistenz. Z Gastroenterol: 45: 843, 2007
Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Pape G, Spengler U, Buggisch P, Balk H, Zankel M, Sarrazin C, Zeuzem S: Zeitspanne bis zur HCV-RNA „Negativierung“ bei Hepatitis C Virus (HCV) Typ 1-Infektion unter Peg-Interferon-alpha-2b plus Ribavirin-Therapie: Unterschiede in Abhängigkeit der Testsensitivität (Indiv-1 Studiengruppe). Z Gastroenterol: 45: 847, 2007
Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grunhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology.: 45: 847, 2007
Cornberg M, Deterding K. Neues zur Virushepatits Forum Sanitas – Das informative Medizinmagazin: 1. Ausgabe; 21, 2007
Schott E, Witt H, Neumann K, Taube S, Oh Djin-Ye, Schreier E, Puhl G, Bergk A, Halangk J, Weich V, Wiedenmann B, Berg T. A toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol: 47(2):203-11., 2007
Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu M, Wiedenmann B, Berg T, Schott E Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma. Am J Gastroenterol.: 102(11):2471-81, 2007
Deterding K, Suneetha PV, Schlaphoff V, Hadem J, Metzler F, Bahr MJ, Manns MP, Cornberg M, Wedemeyer H. Clearance of chronic HCV infection during acute delta hepatitis. Infection: Dec 14, 2007
Schulze A., Gripon P., Urban S. Hepatitis B Virus infection initiates with a large surface protein‐dependent binding to heparan sulfate proteoglycans . Hepatology: 46(6):1759-68, 2007
Buster EHCJ, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HLA for the HBV 99-01 study group. PEGInterferon alpha-2b is safe and effective in HBeAg positive chronic hepatitis B patients with advanced fibrosis. Hepatology: 46(2):388-94, 2007
Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF. Scavenger receptor BI is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology: 46(6):1722-31, 2007
Ahlenstiel G, Roomp K, Daumer M, Nattermann J, Vogel M, Rockstroh JK, Beerenwinkel N, Kaiser R, Nischalke HD, Sauerbruch T, Lengauer T, Spengler U; on behalf of the Kompetenznetz HIV/AIDS. Selective pressures of HLA genotypes and antiviral therapy on HIV-1 sequence mutation and antiviral therapy at a population level. Clin Vaccine Immunol.: 14(10):1266-73, 2007
Potthoff A, Deterding K, Trautwein C, Rifai K, Manns MP, Wedemeyer H. Sustained HCV-RNA response and HBs-seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in an HCV/HBV-coinfected patient. Eur J Gastro Hepatol: 19(10):906-9, 2007
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm S, Janssen HLA. Sustained virological response is associated with an improved clinical outcome for patients with chronic hepatitis C and advanced fibrosis. Ann Intern Medicine: 20;147(10):677-84, 2007
Hofmann WP, Zeuzem S., Sarrazin C. Towards Individualized Antiviral Therapy of Patients Infected with Hepatitis C Virus Genotypes 2 and 3. Hepatology Reviews., 2006/07
Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, vBömmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitits B in HIV-coinfection. AIDS: 20:1951-1954, 2006
Hofmann WP, Bock H, Weber C, Tacke W, Pfaff R, Kihn R, Moog G, Kellner HU, Schofer M, Frick B, Berg P, Rambow A, Friedrich-Rust M, Herrmann E, Sarrazin C, Zeuzem S. [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]. Z.Gastroenterol.: 44,25-31, 2006
Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Pape GR, Spengler U, Buggisch P, Balk H, Zankel M, Sarrazin C, Zeuzem S. 18 Wochen Kombinationstherapie mit Peginterferon Alfa-2b (Peg-IFNa) plus Ribavirin bei „Super-Respondern“ mit Hepatitis C Virus (HCV) Typ 1-Infektion. Z. Gastroenterol: 44: 758, 2006
Witt H, Sahin-Toth M, Landt O, Chen JM, Kahne T, Drenth JP, Kukor Z, Szepessy E, Halangk W, Dahm S, Rohde K, Schulz HU, Le Marechal C, Akar N, Ammann RW, Truninger K, Bargetzi M, Bhatia E, Castellani C, Cavestro GM, Cerny M, Destro-Bisol G, Spedini G, Eiberg H, Jansen JB, Koudova M, Rausova E, Macek M Jr, Malats N, Real FX, Menzel HJ, Moral P, Galavotti R, Pignatti PF, Rickards O, Spicak J, Zarnescu NO, Bock W, Gress TM, Friess H, Ockenga J, Schmidt H, Pfutzer R, Lohr M, Simon P, Weiss FU, Lerch MM, Teich N, Keim V, Berg T, Wiedenmann B, Luck W, Groneberg DA, Becker M, Keil T, Kage A, Bernardova J, Braun M, Guldner C, Halangk J, Rosendahl J, Witt U, Treiber M, Nickel R, Ferec C: A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet.: 38: 668-73., 2006
Mihm U, Grigorian N, Welsch C, Herrmann E, Kronenberger B, Teuber G, von Wagner M, Hofmann WP, Albrecht M, Lengauer T, Zeuzem S, Sarrazin C. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir.Ther.: 11,507-519, 2006
Fytili P, Ciesek S, Bara C, Neipp M, Helfritz F, Haverich A, Klempnauer J, Manns MP, Wedemeyer H. Anti-HBc seroconversion rates after transplantation of anti-HBc positive non-liver organs to anti-HBc negative recipients. Transplantation.: 81,808-809, 2006
van Bömmel F, Mauss S, Wünsche T, Neuhaus R, Reinke P, Schürmann D, Neuhaus P, Wiedenmann B, Berg T. Antivirale Wirksamkeit und Sicherheit von Tenofovir Disoproxil Fumarat (TDF) in der Langzeittherapie der chronischen Hepatitis B Virus (HBV) Infektion bei Monoinfektion, HBV/HIV-Koinfektion und immunsupprimierten Patienten. Z. Gastroenterol: 44: 775, 2006
Schott E, Witt H, Vierich S, Weich V, Halangk J, Bergk A, Sarrazin C, Wiedenmann B, Berg T.. Association of TLR7 Polymorphisms with grade of inflammation and stage of fibrosis in chronic HCV infection Hepatology: 44: 301A, 2006
Henkel, C., Roderfeld, M., Weiskirchen, R., Berres M. L., Hillebrandt, S., Lammert, F., Meyer, H. E., Stuehler K, Graf, J., Roeb, E. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics: 6, 6538-6548, 2006
Engelke, M., Mills, K., Seitz, S., Simon, P., Gripon, P., Schnölzer, M. Urban, S. Characterization of a Hepatitis B and Hepatitis Delta Virus receptor binding site in the preS‐domain of the Hepatitis B Virus large surface protein. Hepatology: 43 (4), 750‐760, 2006
Berg CP, Stein GM, Klein R, Pascu M, Berg T, Kammer W, Priemer M, Nordheim A, Schulze-Osthoff K, Gregor M, Wesselborg S, Berg PA. Characterization of the mitochondrial fraction M4 revealed the predominance of PDC-E1 subunits: re-evaluation of the antibody-frequency to PDC-E1a and –E1b chains in PBC patients J Hepatol: 44:Suppl. 2; S234, 2006
Weich V und Berg T Chronische Hepatitis: Hinweise, Diagnostik, Therapieoptionen Der Hausarzt: 9: 58-64, 2006
Sarrazin C, Gartner BC, Sizmann D, Babiel R, Mihm U, Hofmann WP, von Wagner M, Zeuzem S. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin.Microbiol.: 44,729-737, 2006
Halangk J, Sarrazin C, Puhl G, Teuber G, Klinker H, Buggisch P, Hinrichsen H, Weich V. Bergk A, Wiedenmann B, Neuhaus P, Witt H, Berg T. Complement factor 5 is no genetic risk factor for the progression of liver fibrosis in chronic hepatitis C-infection. J Hepatol: 44:Suppl. 2; S199, 2006
Halangk J, Witt H, Sarrazin C, Puhl G, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T. Complement factor 5 single nucleotide polymorphisms in the progression of liver fibrosis in chronic HCV infection. Hepatology: 44: 578A, 2006
Niederau C, Hippenstiel C. Conservative management of acute pancreatitis: complications and outcome in a community-based hospital. Pancreas: 32,67-79, 2006
Neyzen, S., Van de Leur, E., Borkham-Kamphorst, E., Herrmann, J., Hollweg, G., Gressner, A. M., Weiskirchen, R. Cryopreservation of hepatic stellate cells. J. Hepatol.: 44, 910-917, 2006
Aslan N, Yurdaydin C, Wiegand J, Tillmann HL, Kaiser T, Kulmann B, Bozkaya H, Meyer M, Bozdayi AM, Manns MP, Wedemeyer H. Cytotoxic CD4-positive T cells in viral hepatitis. J Viral Hepatitis: 13, 505-514, 2006
Berg T, von Wagner M, Hinrichsen H, Heintges T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt W, Kallinowski B, Klinker H, Spengler U, Alshuth U. Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. Hepatology: 44: 321A, 2006
Berg CP, Stein GM, Klein R, Pascu M, Berg T, Kammer W, Priemer M, Nordheim A, Schulze-Osthoff K, Gregor M, Wesselborg S, Berg PA: Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver Int.: 26(7):846-55., 2006
Stickel F, Österreicher D, Halangk J, Berg T, Schneider V, Homann N, Hellerbrand C, Kolb A, Friess H, Patsenker E, Seitz H, Schuppan D. Der funktionelle MMP-3 (-1171;5A/6A) Polymorphismus ist kein Risikofaktor für die Entwicklung einer Alkohol-induzierten Leberzirrhose. Z. Gastroenterol: 44: 796, 2006
Schott E, Rieke S, Koch I, Berg T, Wiedenmann B, Scholz A. Z. Die Überexpression von Angiopoietin (Ang)-2 im hepatozellulären Karzinom (HCC) führt zu erhöhten Serum Ang-2 Spiegeln. Gastroenterol: 44: 761, 2006
Fiedler, N., Quant, E., Fink, L., Sun, J., Schuster, R., Gerlich, W.H., Schaefer, S. Differential effects on apoptosis induction in hepatocyte lines by stable expression of hepatitis B virus X protein. World J. Gastroenterol: 12(29): 4673-4682, 2006
Derkow K, Vierich S, Kruse N, Klugewitz K, Mintern J, Wiedenmann B, Berg T, Ploegh H, Schott E. Differential priming of T Cells by antigens expressed in hepatocytes and cholangiocytes in animal models of autoimmune hepatitis and cholangitis. J Hepatol: 44:Suppl. 2; S10, 2006
Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol.: 28,12,3275-82, 2006
Kronenberger B, Herrmann E, Hofmann WP, Wedemeyer H, Sester M, Mihm U, Ghaliai T, Zeuzem S, Sarrazin C. Dynamics of CD81 expression on lymphocyte subsets during interferon-{alpha}-based antiviral treatment of patients with chronic hepatitis C. J Leukoc Biol.: 80,298-308, 2006
Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP and the German HEP NET acute HCV Study Group. Early monotherapy with peginterferon alpha-2b in acute hepatitis C infection: the HepNet Acute-HCV-II study. Hepatology: 43: 250-256,2006
Schott E, Witt H, Halangk J, Weich V, Bergk A, Wiedenmann B, Berg T. Eine Mutation im TLR7 Gen wirkt protektiv hinsichtlich Inflammation und Fibroseprogression bei Patienten mit chronischer Hepatitis C Virus Infektion. Z. Gastroenterol: 44: 782, 2006
McHutchison JG, Afdhal NH, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Blackman N, Campbell FM, Theodore D. Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a phase II placebor controlled, double-blind, dose-ranging study. Hepatology: 44: 692A, 2006
Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, Kieny MP, Pereira CA, Martin JP. ; Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol.: 87(9):2583-93, 2006
Niederau C. Epidemiologie und Übertragung der Hepatitis B. In: Heintges T, Erhardt A, Häussinger D (Hrsg.) Hepatitis B. Thieme Verlag: pp 23-56, 2006
Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Pape GR, Sarrazin C, Zeuzem S. Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise „super-responders“ Hepatology: 44: 319A, 2006
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alpha-2a plus ribavirin. Gastroenterology: 130: 1086-1097, 2006
Fytili P, Dalekos G, Cornberg M, Sarrazin C, Schlaphoff V, Zauner W, Berg T, Zachou K, Manns MP, Klade C, Wedemeyer H. Frequency and functional analysis of variants of the immunodominant epitope NS3-1073: Relevance for vaccine design. Z. Gastroenterol: 44: 770, 2006
Fischer, S.F., Schmidt, K., Fiedler, N., Glebe, D., Schüttler, C., Sun, J., Gerlich, W.H., Repp, R., Schaefer, S. Genotype-dependent activation or repression of HBV enhancer II by transcription factorCOUP-TF 1. World J. Gastroentero: l., 12(37): 6054-6058, 2006
Niederau C. Hämochromatose. KISS-Zeit: pp 1-2, 2006
Seehofer D, Rayes N, Berg T, Neuhaus R, Nüssler, N, Neumann U, Langrehr J, Neuhaus P. HBsAg Serokonversionrate unter Langzeit Adefovir Therapie nach Lebertransplantation. Z. Gastroenterol: 44: 900, 2006
Poynard T, Schiff E, Terg R, Moreno Otero R, Flamm S, Schmidt W, Berg T, Goncales F, Heathcote J, Diago M, McGarrity T, Maieron A, Reichen J, Tanno H, Brandao C, McHutchison J, Silva M, Bedossa P, Deng W, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht JK. HCV RNA negativity after 12 weeks of therapy is the best predictor of sustained viral response (SVR) in the re-treatment of previous interferon-alpha/Ribavirin non-responders (NR): results from the EPIC3 Program. Hepatology: 44: 606A, 2006
Deterding K, Tegtmeyer B, Cornberg M, Hadem J, Potthoff A, Böker KHW, Tillmann HL, Manns MP, Wedemeyer H. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J Hepatol: 45, 770-78, 2006
Rosenau J, Hooman N, Solga T, Rifai K, Tillmann HL, Grzegowski E, Nashan B, Klempnauer J, Strassburg CP, Wedemeyer H, Manns MP. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int: 19, 828-833, 2006

Hepatitis B virus infection: The role of tenofovir as a new promising therapeutic agent. Hepatology Rev: 3: 19-31, 2006
Schäfer M, Mohmand A, Janssen G, Pich M, Schwaiger M, Hinzpeter A, Sarkar R, Friebe A, Weich V, Halangk J, Berg T. Hepatitis C Behandlung bei Patienten mit psychischen Erkrankungen, Methadonsubstitutionstherapie oder früherer Drogenabhängigkeit in Vergleich zu Kontrollen. Z. Gastroenterol: 44: 784, 2006
Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology: 44(3):527-35, 2006
Abou-Dakn M, Niederau C. Hepatitis C. Gynäkologie Geburtshilfe: 1-12, 2006
Berg T. Hepatitis C: Rationale für die Therapie-Individualisierung. Hepatitis & More: 1: 10-12, 2006
Berg T. Hepatitis-B-Infektion – Was ist zu tun? Der Kassenarzt: 6: 26-33, 2006
Niederau C. Hereditary hemochromatosis: when do we treat it? Dtsch Med Wochenschr: 131,1622-23, 2006
Fang X, Zeisel MB, Wilpert J, Gissler B, Thimme R, Kreutz C, Maiwald T, Timmer J, Kern WV, Donauer J, Geyer M, Walz G, Depla E, von Weizsacker F, Blum HE, Baumert TF.. Host cell responses induced by hepatitis C virus binding. Hepatology: 43(6):1326-36, 2006
Wasmuth HE, Wiederholt T, Dahl E, Hellerbrand C, Halangk J, Berg T, Hillebrandt S, Scholten D, Weiskirchen R, Trautwein C, Lammert F. Identification of the chemokine CXCL9 (MIG) as a genetic modifier of liver fibrosis in patients with hepatitis C. Z. Gastroenterol: 44: 760, 2006
Potthoff A, Tillmann HL, Bara C, Deterding K, Pethig K, Meyer S, Haverich A, Böker KHW, Manns MP, Wedemeyer H. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepatitis: 13, 734-41, 2006
Berg T, Weich V, Teuber G, Klinker H, Rasenack J, Hinrichsen H, Pape GR, Spengler U, Buggisch P, Zankel M, Balk H, Sarrazin C, Zeuzem S. Individualized treatment strategy with peginterferon alpha-2b (PEG-IFNα) plus ribavirin according to early viral kinetics in Hepatitis C virus (HCV) type 1 infected patients. J Hepatol: 2; 44:Suppl. 2; S208, 2006
Feldmann G, Nischalke HD, Nattermann J, Banas B, Berg T, Teschendorf C, Schmiegel W, Duhrsen U, Halangk J, Iwan A, Sauerbruch T, Caselmann WH, Spengler U. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non Hodgkin’s lymphoma. Clin Cancer: 12: 4491-4498, 2006
Langrehr PM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, Schonemann C, Krenn V, Neuhaus P, Neumann UP. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl: 12:644-651, 2006
Roderfeld, M., Weiskirchen, R., Wagner, S., Berres, M. L., Henkel, C., Groetzinger, J., Gressner, A. M., Matern, S., Roeb, E. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J.: 20, 444-454, 2006
Frese, M., Bartenschlager, R. Inhibition of hepatitis C virus by nucleic acid-based antiviral approaches. In: Bogner, E. and A. Holzenburg (eds). New concepts of antiviral Therapies. Springer, New York, Dodrecht: ISBN 0-387-31046-0, pp. 47-86, 2006
van Bömmel F, Zöllner B, Möller B, Hüppe D, Feucht H-H, Wiedenmann B, Berg T. Is Tenofovir effective in treatment of adefovir resistant hepatitis B virus (HBV) infections? Hepatology: 44: 567A, 2006
Niederau C. Kapagiannidis C. Epidemiologie der chronischen Hepatitis C in Deutschland. Med Klinik, 101,448-57, 2006
Berg T. Längere Therapiedauer bei HCV-Typ 1-Infektion? Hep-Net NEWS: 1: 03-05, 2006
Berg T. Längere Therapiedauer bei HCV-Typ 1-Infektion? DZKF: 9/10: 35-37, 2006
Niederau C. Metabolische Lebererkrankungen: NASH, Hämochromatose und Morbus Wilson.In: Koinfektion Hepatitis und HIV. Mauss S et al. (Hrsg.) Thieme Verlag: pp 112-128, 2006
Gressner, A. M., Weiskirchen, R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF- as major players and therapeutic targets. J. Cell Mol. Med.: 10, 76-99., 2006
van Bömmel F, Mauss S, Schürmann D, Hüppe D, Neuhaus R, Reinke P, Sarrazin C, Spengler U, Möller B, Zöllner B, Wiedenmann B, Berg T. No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years. Hepatology: 44: 549 A, 2006
Schildgen, O., Helm, M., Gerlich, W.H. Nonreponse to Adefovir: Host or Virus dependent? J. Clin. Virol.: 37: 327-328, 2006
Stark K, Hänel M, Berg T, Schreier E. Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients – epidemiologic and molecular evidence. Arch Virol.: 151:1025, 2006
van Bömmel F, Berg T. Nucleoside and nucleotide anaolgs in chronic hepatitis B virus infection: The role of tenofovir as a new promising therapeutic agent. Hepatology Rev: 3: 19-3, 2006
Neumann UP, Bahra M, Berg T, Scmeding M, Langrehr JM, Neuhaus P. Pegylated interferon alpha-2a treatment in HCV positive patients after liver transplantation. J Hepatol: 44:Suppl. 2; S55, 2006
Funk A, Mhamdi M, Hohenberg H, Will H, Sirma H pH-independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes. Hepatology: 44(3),685-93, 2006
Schaefer M, Hinzpeter A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Uebelhack R, Heinz A, Berg T, Franke L. Platelet Serotonine levels as predictor for the need of antidepressant treatment before and during chronic hepatitis C and interferon-alfa treatment. Hepatology: 44: 268A, 2006
Weich V, Herrmann E, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A Zeuzem S, Berg T. Prediction for treatment outcome in HCV type 1-infected patients: Gamma-Glutamyl Transpepdidase (GGT) is the most reliable independent single parameter. J Hepatol: 44:Suppl. 2; S230, 2006
van Bömmel F, Berg T. Resistenzentwicklung gegenüber Hepatitis-B-Virus (HBV) Polymeraseinhibitoren. In Koinfektion Hepatitis und HIV. Thieme Verlag Hrsg. Rockstroh J, Mauss S, Jäger H.: 44-54, 2006
Gitlin N, Jensen D, Di Bisceglie A, Berg T, Salmeron J, Rizzetto M, Yurdaydin C, Marcellin P. Retreatment with Peginterferon α-2a (40KD) (Pegasys®) plus Ribavirin (Copegus®) in pegylated Interferon α-2b (12KD)/Ribavirin non-responders with cirrhosis / advanced fibrosis: repeat interim analysis. J Hepatol: 44:Suppl. 2; S213, 2006
Tillmann HL, Hadem J, Leifeld L, Zachou K,. Canbay A, Eisenbach C, Graziadei J, Encke J, Schmidt HH, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepatitis: 13,256-63, 2006
Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, Schulze-Osthoff K, Bantel H. Serum detection of intrahepatic caspase activity as a predictive response marker for antiviral therapy in chronic hepatitis C virus infection. Hepatology: 43,1311-6, 2006
Niederau C, Bemba G, Kautz A. Sozio-ökonomische Charakteristika, Lebensqualität und Wissensstand bei Patienten mit Hepatitis C-Virusinfektion in Deutschland. Z Gastroenterol: 44,305-17 , 2006
van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir rescue therapy for patients with lamivudine-resistant hepatitis B virus (HBV) infection showing persistent high level replication during adefovir therapy. Hepatology: 44:318-325, 2006
Wasmuth HE, Wiederhot T, Dahl E, Halangk J, Berg T, Hollebrandt S, Scholten D, Hellerbrand C, Weiskirchen R, Trautwein C, Lammert F. The chemokine CXCL9 (MIG) is a genetic modifier of liver fibrogenesis in chronic hepatitis C. Hepatology: 44: 568A, 2006
Wasmuth HE, Hillebrandt S, Scholten D, Dahmen J, Hellerbrand C, Berg T, Trautwein C, Lammert F. The chemokine CXCL9 (MIG) is associated with liver fibrogenesis in mice and humans. J Hepatol: 44:Suppl. 2; S47, 2006
Scholten D, Dahl E, Berg T, Hellerbrand C, Hillebrandt S, Weiskirchen R, Trautwein C, Lammert F, Wasmuth HE. The fraktalkine receptor CX3CR1 is associated with progression of liver fibrosis in patients with chronic hepatits C. Z. Gastroenterol: 44: 768, 2006
Nattermann J, Ahlenstiel G, Berg T, Muller T, Feldmann G, Nischalke H-D, Rockstroh J, Woitas R, Sauerbruch T, Spengler U. The tandem repeat polymorphism of the DC-SIGNR gene in HCV infection. J Viral Hepat J Viral Hepat: 13: 42-46, 2006
van Bömmel F, Zöllner B, Möller B, Hüppe D, Feucht HH, Wiedenmann B, Berg T. Z. Therapie der chronischen Hepatitis B mit Nukleotid-Analoga: ist Tenofovir bei Adefovir-Resistenz wirksam? Gastroenterol: 44: 774, 2006
Berg T und van Bömmel F. Therapie der chronischen Hepatitis B. Verdauungskrankheiten: 4: 185-197, 2006
Berg T. Therapie der Hepatitis B – Aktueller Stand und Perspektiven. Der Gastroenterologe2: 117-125, 2006:
Berg T. Therapie-Individualisierung bei chronischer Hepatitis C: Update. Hepatitis & More: 2: 12-16, 2006
Niederau C. Therapieoptionen bei chronischer Hepatitis. Internist: 47:308-310, 2006
Erhardt, A.H., Gerlich, W.H., Starke, C., Wend, U., Donner, A., Sagir, A., Heintges, T., Häussinger. D. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int.: Sep; 26(7): 805-810, 2006
Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, Neuhaus P. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation: 15:43-7, 2006
Gressner, A. M., Lahme, B., Meurer, S. K., Gressner, O., Weiskirchen, R. Variable expression of Cystatin C in cultured transdifferentiating rat hepatic stellate cells. World J. Gastroenterol: 12, 731-738, 2006
Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. ; Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol.: 80(21):10579-90, 2006
Popov Y, Patsenker E, Bauer M, Schulze-Krebs A, Niedibitek E, Schuppan D. Halofuginone Induces Matrix Metalloproteinases in Rat Hepatic Stellate Cells via Activation of p38 and NFkB; JBC.: 2005
Popov Y, Patsenker E, Fickert P, Trauner M, and Schuppan D. MDR2 (ABCB4) -/- Mice spontaneously Develop Severe Biliary Fibrosis via Massive Dysregulation of Pro- and Antifibrogenic Genes J Hepatol.: 2005
Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M, Schuppan D. Hepatitis C virus replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology:2005
Potthoff A, Sarhaddar J, Wiegand J, Lichtinghagen R, Sarrazin C, Ciner A, Hadem J, Trautwein C, Manns MP, Wedemeyer H Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. Hepatology Research: Jan;31(1):18-23, 2005
Nattermann J*, Ahlenstiel G, Berg T, Muller T, Feldmann G, Nischalke H-D, Rockstroh J, Woitas R, Sauerbruch T, Spengler U. The tandem repeat polymorphism of the DC-SIGNR gene in HCV infection. J Viral Hep.: 2005
Weiskirchen, R., Gressner, A. M. J. Varga, D. Brenner, and P. Shen (eds) Isolation and culture of hepatic stellate cells. In Methods in Molecular Medicine: Fibrosis Research, Liver Section. Humana Press, Totowa, NJ, USA: S.99- S.113., 2005
Grassmann, C.W., Yu, H., Isken, O., and Behrens, S.-E. Hepatitis C virus and the related bovine viral Diarrhea virus considerably differ in the functional organization of the 5’ non-translated region: implications for the viral life cycle Virology: 333: 349-366, 2005
aus dem Siepen M, Viazov S, Wiese M, Lohmann V, Roggendorf M. NS5A does not contribute to the resistance of HCV replication to interferon-alpha in cell culture Virology: 336, 131-136, 2005
G. Feldmann, J. Nattermann, B. Banasch, H.D. Nischalke, G. Ahlenstiehl, T. Kuntzen, M. Schulz, R. Woitas, C. Teschendorf, W. Schmiegel, T. Sauerbruch, U. Spengler. Induktion von Interleukin-6 durch HCV core-Protein bei Hepatitis C-assoziierten Kryoglobulinämien und B-Zell Non-Hodgkin-Lymphomen. J Hepatol Abstract Book EASL: 42 Suppl. 2; 157, 2005
Potthoff A, Sarhaddar J, Wiegand J, Lichtinghagen R, Sarrazin C, Ciner A, Hadem J, Trautwein C, Manns MP, Wedemeyer H. Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse Hepatology Research: 31(1):18-23., 2005
Kempf VAJ., Schairer A, Neumann D, Grassl GA, Lauber K, Lebiedziejewski M, Schaller M, Kyme P, Wesselborg S, Autenrieth IB Bartonella henselae inhibits apoptosis in Mono Mac 6 cells. Cell. Microbiol.: 7:91-104, 2005
Holtick U, Vockerodt M, Pinkert D, Schoof N, Stürzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Löffler D, Horn F, Trümper L, Kube D STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia: 19:936-44., 2005
Hillebrandt, S., Wasmuth, H. E., Weiskirchen, R., Keppeler, H., Werth, A., Wilkens, G., Geier, A., Hellerbrand, C., Lorenzen, J., Gressner, A. M., Matern, S., Lammert, F. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans Nature Genet.: 37, 2005
Wang, H., Mengsteab, S., Tag, C. G., Gao, C. F., Hellerbrand, C., Lammert, F., Gressner, A. M., Weiskirchen, R. Transforming growth factor-1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol: 11, 1929-1936., 2005
Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol.: 42(6):793-8, 2005
Funk, A., Lin, L., Mhamdi. M., Will. H. and Sirma, H. Determinants of hepadnaviral species and liver tropism. In: Animal Models for Hepatitis Viruses. M. Roggendorf and F.v. Weizsäcker, Monographs of Virology: 56-65, 2005
M. Roggendorf and F.v. Weizsäcker Animal Models for Hepatitis Viruses Monographs of Virology: Buch, 2005
W.O. Böcher, Y. Reisner. The trimera mouse model of HBV and HCV infection. Monogr Virol: 146-160., 2005
Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, Bach K, Geier A, Purucker EA, Gressner AM, Matern S, Lammert F Patients with acute on chronic liver failure display "sepsis-like" immunoparalysis. J Hepatol: 42:195-201, 2005
Berg T. Interview Lebenszeichen: 4: 16-17, 2005
aus dem Siepen, M, Lohmann V, Wiese M, Ross S, Roggendorf M, Viazov S. Nonstructural protein 5A does not contribute to the resistance of hepatitis C virus replication to interferon alpha in cell culture. Virology: 336, 131-136, 2005
Wesselborg S, Lauber K Mechanisms of anticancer drug action. In: "Apoptotic pathways as target for novel therapies of cancer and other diseases" edited by M. Los & S.B Gibson; Kluwer Academic Press, (2005), ISBN: 0-387-23384-9., 2004
Fleig,WE, P Krummenerl, J Lesske, H P Dienes, S Zeuzem, W H Schmiegel, D Haussinger, M Burdelski, M P Manns [Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]: Z.Gastroenterol.: v. 42, p. 703-704, 2004
Manns,MP, H Wedemeyer, S Meyer, M Roggendorf, C Niederau, H E Blum, W Jilg, W E Fleig [Diagnosis, progression and therapy of hepatitis-B-virus infection--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]: Z.Gastroenterol: v. 42, p. 677-678., 2004
Schirmacher,P, W E Fleig, A Tannapfel, C Langner, V Dries, L Terracciano, H Denk, H P Dienes [Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet)] Pathologe: v. 25, p. 337-348., 2004
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med.: Mar 2;140(5):370-81, 2004
Hans L. Tillmann, Michael P. Manns, Christa Claes, Hans Heiken, Reinhold E. Schmidt, Matthias Stoll. GB Virus C Infection and Quality of Life in HIV positive Patients. AIDS Care: Aug;16(6):736-43, 2004
Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C genotype 3 infection. J Med Virol: 73: 387-391, 2004
Christoph Sarrazin, Thomas Berg, Viola Weich, Tobias Mueller, Ulrich H. Frey, Stefan Zeuzem, Guido Gerken, Michael Roggendorf and Winfried Siffert. GNB3 C825T polymorphism and response to interferon-alfa /ribavirin treatment in patients with hepatitis C virus genotype 1 2004
Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kutbitschke A, Aslan N, Tillmann HL, Manns MP and Wedemeyer H Long-term Follow-up After Successful Interferon Therapy of Acute Hepatitis C. Hepatology: 40: 98-107., 2004
Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hep: 11: 519-26., 2004
Marcus Ritter, Mona Y. Ali, Christian F. Grimm, Robert Weth, Leonhard Mohr, Wulf O.Bocher, Katja Endrulat, Heiner Wedemeyer, Hubert E. Blum, and Michael Geissler . Immunoregulation of dendritic and T cells by alphafetoprotein in patients with hepatocellular carcinoma. J Hepatol.: Dec;41(6):999-1007, 2004
M. Ali, C. Grimm, M. Ritter, L. Mohr, H.P. Allgaier, R. Weth, W.O. Böcher, K. Endrulat, H.E. Blum, M. Geissler. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatology: 2004
Norbert Hubert Gruener, Maria-Christina Jung, Axel Ulsenheimer, Joern Tilman Gerlach, Reinhart Zachoval, Helmut M. Diepolder, Gustavo Baretton, Rolf Schauer, Gerd Rudolf Pape, and Albrecht Carl Albrecht Schirren Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-Infection after orthotopic liver transplantation. Liver Transplantation: 10: 1487-1496., 2004
Mascheretti S*, Hinrichsen H*, Ross S, Buggisch P, Hampe J, Fölsch UR, Schreiber S Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol: 136: 328-333, 2004
Janoschek, N., van de Leur, E., Gressner, A. M., Weiskirchen, R. Induction of cell death in activated hepatic stellate cells by target gene expression of the thymidine kinase/Ganciclovir system. Biochem. Biophys. Res. Commun.: 316, 1107-1115., 2004
Lauber K, Blumenthal SG, Waibel M, Wesselborg S Clearance of apoptotic cells: getting rid of the corpses. Mol. Cell: 10: 1463-1470, 2004
Stoll, C., Mengsteab, S., Stoll, D., Riediger, D., Gressner, A. M., Weiskirchen, R. Analysis of polymorphic TGFB1 codons 10, 25, 263 in a German patient group with nonsyndromic cleft lip, alveolus, and palate compared with healthy controls. BMC Med Genet: 5 (15), 1-9, 2004
Brügmann, M., Gressner, A. M., Matern, S., Lammert, F. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C Liver Int.: 24, 285-294., 2004
Wasmuth HE, Werth A, Müller T, Berg T, Dietrich CG, Geier A, Schirin-Sokhan R, Gartung C, Lorenzen J, Matern S, Lammert F. CC Chemokine Receptor 5 32 polymorphism in two independent cohorts of HCV infected Caucasian patients without hemophilia. J Mol Med: 82:64-69, 2004
T. Berg. Therapie der chronischen Hepatitis C.; Med Welt: 55: 220-7., 2004
Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J, Matern S, Lammert F. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis: 4:1-8, 2004
Mueller T, Andreas Mas-Marques, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Wiedenmann B, Schreier E, Berg T. Influence of Interleukin 12B (IL12B) Polymorphisms on Spontaneous and Treatment-induced Recovery from Hepatitis C Virus (HCV) Infection. J Hepatol: 41: 652-658, 2004
Halangk, J, Berg T, Puhl G, Müller T, Nickel R, Kage A, Landt O, Luck W, Wiedenmann B, Neuhaus P, Witt H. Keratin 8 Y54H and G62C mutations are not associated with liver disease J Med Gen: 41: E92., 2004
Saile B, DiRocco P, Dudas J, El-Armouche H, Sebb H, Eisenbach C, Neubauer K, Ramadori G. IGF-I induces DNA synthesis and apoptosis in rat liver hepatic stellate cells (HSC) but DNA synthesis and proliferation in rat liver myofibroblasts (rMF). Lab Invest: 84; 1037-1049., 2004
Saile B, Eisenbach C, Dudas J, El-Armouche H, Ramadori G. Interferon-gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates the antiapoptotic effect of interferon-alpha by an HSP70-dependant pathway. Eur J Cell Biol: 83;469-476, 2004
Lammert F, Wilkens G, Dietrich CG, Geier A, Wasmuth HE, Matern S. Extrahepatische Manifestationen chronischer Lebererkrankungen. Versicherungsmedizin: 57:64-71, 2004
Henkel, C., Roderfeld, M., Weiskirchen, R., Scheibe, B., Matern, S., Roeb, E. Identification of fibrosis relevant proteins using DIGE (Difference in Gel electrophoresis) in different fibrosis models Z Gastroenterol: 43, 23-29, 2004
Zeuzem S. Standardtherapie der akuten und chronischen Hepatitis C. Z Gastroenterol: Aug;42(8):714-9, 2004
Niederau C. Therapie der Hepatitis B: State-of-the-art Med Welt: 55:211-215, 2004
Polywka S & Laufs R. Aktuelle Stillempfehlung bei chronischer Hepatitis C der Mutter. Newsletter „Gesundheitsforschung“ of the „Bundesministerium für Bildung und Forschung“,2004
Ross RS, Roggendorf M Übertragungsrisiko von HBV, HCV und HIV durch infiziertes medizinisches Personal. Lengerich et al. (Pabst Science Publishers), 2004

Jahresberichte zur Epidemiologie der Virushepatitis B und C in Deutschland 2003 bzw. 2004 RKI: Epidemiologisches Bulletin 2004, Nr. 2, Seiten 11-17; RKI:Epidemiologisches Bulletin: Nr. 37, Seiten 307-315, 2004
Fleig WE, Krummenerl P, Leßke J. Indikationsstellung akute/chronische Hepatitis C. Z Gastroenterol.: Aug;42(8):707-13, 2004
Schmiegel WH Diagnostik und Therapie der akuten und chronischen Hepatitis C – Vorgehen in Probelmsituationen. Z Gastroenterol: Aug;42(8):720-3., 2004
Dienes HP Definition und Diagnostik der akuten und chronischen Hepatitis C Z Gastroenterol, Aug;42(8):705-6., 2004
P. Schirmacher, W.E. Fleig, H.P. Dienes Biopsy Diagnosis of Chronic Hepatitis – Results of an Evidence-Based Consensus Conference of the German Society of Pathology (DGP), the German Society for Digestive and Metabolic Diseases (DGVS), and the Network of Competence for Hepatitis (HepNet). Z Gastro: 42: 175-185., 2004
Müller TH, Weiss K, Adelhard K: Zentrale IT-Strukturen für vernetzte medizinische Forschung und Versorgung im Kompetenznetz Hepatitis In: Ammenwerth E, Gaus W, Haux R, Lovis C, Pfeiffer KP, Tilg B, Wichmann HE (ed) „Kooperative Versorgung Vernetzte Forschung Ubiquitäre Information, 222-224, Verlag videel , Niebüll, 2004
Manns MP, Caselmann WH, Wiedmann KH, Wedemeyer H. Standardtherapie der chronischen Hepatitis B. Z Gastroenterol.: Aug;42(8):687-91, 2004
Manns MP, Wedemeyer H, Meyer S, Roggendorf M, Niederau C, Blum HE, Jilg W, Fleig WE. Diagnose, natürlicher Verlauf und Therapie der Hepatitis-B-Virus Infection Z Gastroenterol.: Aug;42(8):677-8., 2004
Wedemeyer H., Meyer S. & Manns M.P.. Kompetenznetz Hepatitis (Hep-Net). Internist (Berl): 45:415-421, 2004
S. Tavakoli, W. Schwerin, A. Rohwer, S. Hoffmann, S. Weyer, R. Weth, H. Meisel, H. Diepolder, M. Geissler, P.R. Galle, H. F. Löhr and W.O. Böcher. Phenotype and Function of Monocyte derived Dendritic Cells in Chronic Hepatitis B Virus Infection J Gen Virol: 85: 2829-2836., 2004
Rösler C, Köck J, Malim MH, Blum HE, von Weizsäcker F. Comment on „Inhibition of Hepatitis B Virus Replication by APOBEC3G. Science: 305, 3, September, 2004
Isken, O., Grassmann, C.W., Yu, H., and Behrens, S.-E. Complex signals in the genomic 3’ non-translated region of bovine viral diarrhea virus coordinate translation and replication of the viral RNA. RNA: 10: 1637-52., 2004
Bartenschlager, R., and S. Sparacio In vitro replication models of HCV. In: H. Thomas, A. Zuckermann, S. Lemon (eds.), Viral Hepatitis, 3rd edition, 2004
Frese, M., V. Lohmann, T. Pietschmann, A. Kaul, N. Krieger, J. Bukh, and R. Bartenschlager. Hepatitis C virus replication in cell culture. In: M. Omata, K. Okita (eds.), Therapy for viral hepatitis and prevention of hepatocellular carcinoma, 108-122., 2004
Bartenschlager, R., M. Frese, and T. Pietschmann. 2004 Novel insights into hepatitis C virus replication and persistence. Advances in Virus Research: 63:71-180, 2004
Mihm, S., M. Frese, V. Meier, P. W. Braun, J. G. Scharf, R. Bartenschlager, and G. Ramadori. Interferon type I gene expression in chronic hepatitis C. Laboratory Investigation: 84(9):1148-59, 2004
Krönke, J., R. Kittler, F. Buchholz, M. Windisch, T. Pietschmann, R. Bartenschlager, and M. Frese. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. Journal of Virology: 78:3436-3446, 2004
Funk, A., Hohenberg, H., Mhamdi, M., Will. H. and Sirma, H. Spread of hepatitits B virus in vitro requires extracellular progeny and may be codetermined by polarized Egress J Virol.: Apr;78(8):3977-83., 2004
F. Tacke, C. Gehrke, T. Luedde, A. Heim, M. P. Manns & C. Trautwein Basal Core Promoter and Precore Mutations in the Hepatitis B Virus Genome Enhance Replication Efficacy of Lamivudine-Resistant Mutants. J Virol.: August; 78(16): 8524–8535, 2004
Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology: 40: 1442-1449, 2004
van Bommel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T Comparison of Adefovir and Tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology: 40: 1421-1425, 2004
Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, Zeuzem S. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? Hepatology: 39: 1456-1457, 2004
Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, Schreier E, Berg T. Sustained virologic response in HCV type 1b-infected patients is predicted by the number of mutations within the NS5A-ISDR: A meta analysis focussed on geographical differences, Gut: 53: 1345-1351, 2004
Wasmuth HE, Werth A, Mueller T, Berg T, Dietrich CG, Geier A, Gartung C, Lorenzen J, Matern S, Lammert F. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology, 40: 327-334.,2004
Nattermann J, Nischalke HD, Kupfer B, Rockstroh J, Hess L, Sauerbruch T, Spengler U. Regulation of CC-chemokine receptor 5 in hepatitis G virus infection. AIDS: 17:1457-1462, 2003
Berg,T, C Sarrazin, E Herrmann, H Hinrichsen, T Gerlach, R Zachoval, B Wiedenmann, U Hopf, S Zeuzem Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy: Hepatology: v. 37, p. 600-609, 2003
Berg, T., Kronenberger, B., Hinrichsen, H., Gerlach, T., Buggisch, P., Herrmann, E., Spengler, U., Goeser, T., Nasser, S., Wursthorn, K., Pape, G.R., Hopf, U., Zeuzem, S.: Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology: 37: 1359-1367, 2003
Manns MP, Meyer S. & Wedemeyer H. The German Network of Excellence for Viral Hepatitis (Hep-Net). Hepatology: Sep;38(3):543-4., 2003
Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, Wyen C, Schmitz K, Sauerbruch T, Rockstroh JK. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Eur J Med Res: 8:56-60, 2003
Arias, M., Sauer-Lehnen, S., Treptau, J., Janoschek, N., Theuerkauf, I., Buettner, R., Gressner, A. M., Weiskirchen, R. Adenoviral expression of a transforming growth factor-1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterology: 3 (29), 1-12., 2003
Lichterfeld M, Nischalke HD, van Lunzen J, Söhne J, Woitas R, Sauerbruch T, Rockstroh J, Spengler U. The tandem-repeat polymorphism of the DC-SIGNR gene does not affect susceptibility to HIV infection and the progression to AIDS. Clin Immunol: 107:55-59, 2003
Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut W, Schirren CA, Waechtler M, Backmund M, Pape GR Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology: Jul; 125 (1): 253-6, 2003
Axel Ulsenheimer, Tilman J. Gerlach, Norbert H. Gruener, Maria-Christina Jung, Carl A. Schirren, Winfried Schraut, Reinhart Zachoval, Gerd R. Pape, Helmut M. Diepolder Detection of funcionally altered hepatitis C virus specific CD4 T cells in acute and chronic hepatitis C Hepatology: May, 37 (5) 1189-98, 2003
Quirishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh J, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection . Lancet: 362: 1708-13, 2003
Tag, C. G., Mengsteab, S., Hellerbrand, C., Lammert, F., Gressner, A. M., Weiskirchen, R. Analysis of the transforming growth factor-1 (TGF-1) codon 25 gene polymorphism by LightCycler-analysis in patients with hepatitis C infection. Cytokine: 24, 173-181, 2003
Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S Effect of ribavirin on Hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology: 37: 1351-1358, 2003
Kubitschke A, Bahr M, Aslan N, Sarrazin C, Tillmann HL, Greten T, Meyer M, Wiegand J, Manns MP, Wedemeyer H. Induction of hepatitis C virus specific T cells by needle stick injury in the absence of HCV-viremia. Hepatology: 38: Suppl. 1, 172A, 2003
Nencioni, A., Lauber, K., Grünebach, F., van Parijs, L., Denzlinger, C., Wesselborg, S., Brossart, P. Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J. Immunol: 171: 5148-56,2003
Lauber, K.L., Bohn, E., Kröber, S.M., Xiao, Y.J., Blumenthal, S.G., Lindemann, R.K., Marini, P., Wiedig, C., Zobywalski, A., Baksh, S., Xu, Y., Autenrieth, I.B., Schulze-Osthoff, K., Belka, C., Stuhler, G., Wesselborg, S. Apoptotic cells induce migration of phagocytes via caspase-3 mediated release of a lipid attraction signal. Cell.: 113: 717-730, 2003
Mueller T, Gessner R, Sarrazin C, Graf C, Halangk J, Witt H, Kottgen E, Wiedenmann B, Berg T. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology: 38: 1592., 2003
Wasmuth HE, Lammert F, Matern S. Genetische Risikofaktoren der Fibrogenese bei chronischen Lebererkrankungen Med Klinik: 98:754-762., 2003
Polywka S, Feucht H-H & Laufs R. Chronic hepatitis C virus infection is no contraindication for breast feeding. Bundesgesundheitsblatt: 46, 739-743., 2003
Cornberg M, Hüppe D, Wiegand J, Felten G, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3 Z Gastroenterol.: Jun;41(6):517-22, 2003
Schreier E, Radun D, Neuhauser H, Stark K. Hepatitis C. Gesundheitsberichterstattung des Bundes, Robert Koch-Institut: Berlin, Heft 15, 2003
Reng CM, Debold P, Adelhard K, Pommerening K Akzeptiertes Datenschutzkonzept. Dtsch Ärzteblatt: 100: A 2134-2137 [Heft 33],2003
Wedemeyer H & Meyer S., Manns M. P. & Wedemeyer, H. Kompetenznetz Hepatitis. In: Handbuch der Hepatitis C: Diagnostik, Verlauf, Therapie. (Hrsg.), 114-117. Bremen: Uni-med Verlag., 2003
Isken, O., Grassmann, C.W., Sarisky, R.T., Kann, M., Zhang, S., Grosse, F., Kao, P.N., and Behrens, S.-E. Members of the NF90/NFAR protein group are involved in the life cycle of a positive-strand RNA virus. EMBO J.: 22: 5655-5665., 2003
Frese, M., K. Barth, A. Kaul, V. Lohmann, V. Schwärzle, and R. Bartenschlager. Hepatitis C virus RNA replication is resistant to tumor necrosis factor-alpha. Journal of General Virology: 84:1253-1259., 2003
Bartenschlager R, Kaul A, Sparacio Replication of the hepatitis C virus in cell culture. S. Antiviral Res.: Oct;60(2):91-102, 2003
Vrolijk, J., A. Kaul, B.E. Hansen, V. Lohmann, S.W. Schalm, and R. Bartenschlager. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Journal of Virological Methods: 110:201-209, 2003
Bartenschlager, R., M. Frese, and T. Pietschmann. Novel insights into hepatitis C virus replication and persistence. Advances in Virus Research: 63:71-180, 2003
Klein C, Bock CTB, Wedemeyer H., Wustefeld T., Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology, 125: 9-18, 2003
Lammert F, Hillebrandt S, Matern S. Identification of fibrogenic genes in a polygenic mouse model of liver fibrosis. In: Gressner AM, et al. (Hrsg.). Cytokines in liver injury and repair. Kluwer Academic Publishers, Dordrecht: S. 173-176, 2002
Viazov S, Ross S, Roggendorf M. Hepatitis C virus persistence: role of viral factors in escape from the innate immune surveillance, Update in Hepatology: 10-27, 2002.
Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology: 123:2041-2051, 2002
Norbert H. Gruener, Maria-Christina Jung, Axel Ulsenheimer, Tilman J. Gerlach, Helmut M. Diepolder, Carl A. Schirren, Robert Hoffmann, Martin Wächtler, Markus Backmund, Gerd R. Pape Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. Journal of Hepatology: 37; 866-869, 2002
Jaeckel,E, M Cornberg, H Wedemeyer, T Santantonio, J Mayer, M Zankel, G Pastore, M Dietrich, C Trautwein, M P Manns Treatment of acute hepatitis C with interferon alfa-2b N.Engl.J.Med: v. 345, p. 1452-1457, 2001
Artikelaktionen
Ansprechpartner:
Nina Schmidt
Teamassistentin
Telefon +49(0)511 532 6819
Schmidt.Nina@mh-hannover.de

Bianka Wiebner
Hauptgeschäftsführerin
Telefon +49(0)511 532 6815
Wiebner.Bianka@mh-hannover.de